ReviewCureus2026
Von Hippel-Lindau Syndrome: An Updated Narrative Review for the First-Contact Clinician.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Von Hippel-Lindau (VHL) syndrome is an autosomal dominant (AD) condition that increases the risk of developing CNS and retinal hemangioblastomas (R-Hb), as well as clear cell renal cell carcinoma (ccRCC), pheochromocytomas, pancreatic neuroendocrine tumors (pNETs), and endolymphatic sac tumors. CNS hemangioblastomas and renal cell carcinomas are among the leading causes of mortality in affected individuals. Recent therapeutic advances, particularly hypoxia-inducible factor 2 alpha (HIF-2α) inhibitors and vascular endothelial growth factor (VEGF)-targeted therapies, have yielded promising results. However, active surveillance remains the cornerstone of clinical management for reducing associated morbidity and mortality. Because VHL syndrome is multisystemic, a multidisciplinary clinical team is necessary to provide comprehensive care, including targeted pharmacotherapy and surgical resection, to prevent severe complications. This narrative review outlines the current diagnostic approach and follow-up protocols for VHL syndrome, highlighting recent therapeutic advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.